MarketCap
Facebook
X
Telegram
Global Cord Blood Corporation Income Statement 2022-2009 | CO
Brief overview of income trends at Global Cord Blood Corporation
The overview follows changes across a five-year period. Revenue at Global Cord Blood Corporation moved from 760 million yuan in 2017 to 1.2 billion yuan in 2022. Overall revenue changed by +63.6%, equal to an annualized rate of about 10.3%. Top-line growth remained consistently strong over the period.
Gross profit was 617 million yuan at the start and 1.1 billion yuan at the end of the period (+71.7%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 81.2% to 85.3%. Improving gross profitability strengthens the quality of revenue growth.
The operating result measured by EBITDA moved from 311 million yuan to 652 million yuan, or +109.9%. Operating profitability strengthened faster than the scale of sales. Comparing the endpoints gives EBITDA margins of 40.9% and 52.5%. Higher profitability strengthens the quality of operating growth.
The net result moved from 126 million yuan to 501 million yuan, or +297.1%. Net income grew faster than revenue, indicating improved overall efficiency.
Market capitalization changed from 745 million yuan to 304 million yuan (−59.2%). Investors remain cautious despite better financial results.
Conclusion
The results present an uneven picture without one dominant signal. The strongest signals are better sales economics, positive operating leverage and net-income growth. The most visible risks are a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Global Cord Blood Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
304 M | 486 M | 470 M | 564 M | 709 M | 745 M | 420 M | 428 M | 334 M | 277 M | 190 M | 174 M | - | - |
Shares |
122 M | 122 M | 122 M | 121 M | 113 M | 73 M | 73 M | 73 M | 73 M | 71.5 M | 73.9 M | 70.1 M | - | - |
Historical Prices |
2.5 | 4 | 3.87 | 4.65 | 6.28 | 10.2 | 5.75 | 5.86 | 4.58 | 3.87 | 2.57 | 2.48 | ||
Net Income |
501 M | 508 M | 471 M | 291 M | 237 M | 126 M | 91 M | 107 M | 132 M | 112 M | 132 M | 91.7 M | 49.2 M | - |
Revenue |
1.24 B | 1.16 B | 1.22 B | 987 M | 937 M | 760 M | 663 M | 635 M | 573 M | 526 M | 380 M | 340 M | 262 M | - |
Cost of Revenue |
183 M | 179 M | 189 M | 186 M | 181 M | 143 M | - | - | - | 107 M | 86.7 M | 77.4 M | 65.7 M | - |
Gross Profit |
1.06 B | 981 M | 1.03 B | 801 M | 755 M | 617 M | 518 M | 505 M | 467 M | 420 M | 294 M | 262 M | 196 M | - |
Operating Income |
609 M | 545 M | 559 M | 382 M | 280 M | 265 M | 191 M | 235 M | 232 M | 209 M | 135 M | 124 M | 97.2 M | - |
Interest Expense |
6.27 M | 8.16 M | 7.39 M | 5.7 M | 3.26 M | 119 M | 108 M | 101 M | 70.1 M | 70.1 M | 3.29 M | 2.61 M | 2.43 M | - |
EBITDA |
652 M | 589 M | 604 M | 429 M | 326 M | 311 M | 237 M | 281 M | 264 M | 241 M | 160 M | 146 M | 117 M | - |
Operating Expenses |
451 M | 436 M | 473 M | 419 M | 475 M | 352 M | 327 M | 270 M | 235 M | 210 M | 159 M | 138 M | 98.6 M | - |
General and Administrative Expenses |
187 M | 174 M | 190 M | 169 M | 244 M | 190 M | 170 M | 132 M | 112 M | 108 M | 89.7 M | 83.8 M | 53.3 M | - |
All numbers in CNY currency
Quarterly Income Statement Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q1 | 2009-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | 122 M | - | 122 M | 122 M | 122 M | - | 122 M | 122 M | 122 M | - | 122 M | 121 M | 121 M | - | 121 M | 114 M | 113 M | - | 114 M | 73 M | 73 M | - | 73 M | 73 M | 73 M | - | 73 M | 73 M | 73 M | - | 73 M | - | 73 M | - | 73 M | 73 M | 71.5 M | - | 69.9 M | 69.9 M | 73.9 M | 73.2 M | 73.2 M | 73.6 M | 70.1 M | - | - |
Net Income |
- | - | - | 501 M | - | 126 M | 126 M | 508 M | - | 131 M | 120 M | 471 M | - | 120 M | 65.1 M | 291 M | - | 65.1 M | 67.6 M | 237 M | - | 67.6 M | 16.6 M | 126 M | - | 16.6 M | 18.7 M | 91 M | - | 18.7 M | 27.2 M | 107 M | - | 27.2 M | - | 132 M | - | 24.9 M | 24.9 M | 112 M | - | 24.7 M | 24.7 M | 132 M | 39.5 M | 39.5 M | 23.2 M | 91.7 M | 49.2 M | - |
Revenue |
- | - | - | 1.24 B | - | 314 M | 314 M | 1.16 B | - | 286 M | 313 M | 1.22 B | - | 313 M | 247 M | 987 M | - | 247 M | - | 937 M | - | 235 M | - | 760 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 142 M | 142 M | 129 M | - | 128 M | 128 M | 380 M | 94.8 M | 94.8 M | 98.4 M | 340 M | 262 M | - |
Cost of Revenue |
- | - | - | 183 M | - | 46.2 M | 46.2 M | 179 M | - | 44.7 M | 48.3 M | 189 M | - | 48.3 M | 47.3 M | 186 M | - | 47.3 M | - | 181 M | - | 45.6 M | - | 143 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.4 M | 27.4 M | 24.5 M | - | 27.1 M | 27.1 M | 86.7 M | 21.7 M | 21.7 M | 21.8 M | 77.4 M | 65.7 M | - |
Gross Profit |
- | - | - | 1.06 B | - | 267 M | 267 M | 981 M | - | 241 M | 265 M | 1.03 B | - | 265 M | 200 M | 801 M | - | 200 M | 189 M | 755 M | - | 189 M | 145 M | 617 M | - | 145 M | 134 M | 518 M | - | 134 M | 122 M | 505 M | - | 122 M | - | 467 M | - | 114 M | 114 M | 420 M | - | 101 M | 101 M | 294 M | 73.1 M | 73.1 M | 76.7 M | 262 M | 196 M | - |
Operating Income |
- | - | - | 609 M | - | 160 M | 160 M | 545 M | - | 139 M | 144 M | 559 M | - | 144 M | 105 M | 382 M | - | 105 M | 76.3 M | 280 M | - | 76.3 M | 54.7 M | 265 M | - | 54.7 M | 52.5 M | 191 M | - | 52.5 M | 57.5 M | 235 M | - | 57.5 M | - | 232 M | - | 56.3 M | 56.3 M | 209 M | - | 47 M | 47 M | 135 M | 31.5 M | 31.5 M | 37.7 M | 124 M | 97.2 M | - |
Interest Expense |
- | - | - | 6.27 M | - | 583 K | 583 K | 8.16 M | - | 1.2 M | 422 K | 7.39 M | - | 422 K | 3.26 M | 5.7 M | - | -56 K | 3.26 M | 3.26 M | - | 993 K | 29.8 M | 119 M | - | 29.8 M | 26.3 M | 108 M | - | 26.3 M | 25.2 M | 101 M | - | 25.2 M | - | 70.1 M | - | 16.5 M | 16.5 M | 70.1 M | - | 14.1 M | 14.1 M | 3.29 M | 741 K | 741 K | 1.19 M | 2.61 M | 2.43 M | - |
EBITDA |
- | - | - | 652 M | - | 172 M | 172 M | 589 M | - | 150 M | 156 M | 604 M | - | 156 M | 117 M | 429 M | - | 117 M | 87.5 M | 326 M | - | 87.5 M | 66.2 M | 311 M | - | 66.2 M | 63.9 M | 237 M | - | 63.9 M | 69.6 M | 281 M | - | 69.6 M | - | 264 M | - | 63.8 M | 63.8 M | 241 M | - | 54.2 M | 54.2 M | 160 M | 31.5 M | 37.5 M | 37.7 M | 146 M | 117 M | - |
Operating Expenses |
- | - | - | 451 M | - | 107 M | 107 M | 436 M | - | 102 M | 121 M | 473 M | - | 121 M | 95.1 M | 419 M | - | 95.1 M | 113 M | 475 M | - | 113 M | 90.3 M | 352 M | - | 90.3 M | 81.8 M | 327 M | - | 81.8 M | 64.3 M | 270 M | - | 64.3 M | - | 235 M | - | 58 M | 58 M | 210 M | - | 54.4 M | 54.4 M | 159 M | 41.6 M | 41.6 M | 39 M | 138 M | 98.6 M | - |
General and Administrative Expenses |
- | - | - | 187 M | - | 44.5 M | 44.5 M | 174 M | - | 42.7 M | 49.4 M | 190 M | - | 49.4 M | 40 M | 169 M | - | 40 M | 52.8 M | 244 M | - | 52.8 M | 48.3 M | 190 M | - | 48.3 M | 42.6 M | 170 M | - | 42.6 M | 31 M | 132 M | - | 31 M | - | 112 M | - | 28 M | 28 M | 108 M | - | 29 M | 29 M | 89.7 M | 22.7 M | 22.7 M | 21.4 M | 83.8 M | 53.3 M | - |
All numbers in CNY currency
The income statement is one of the three key financial reports of a company Global Cord Blood Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Germany
Canada
Niderland
Britain
Israel
Australia
China
Irlanda
Schweiz
